9G6Q

scFv IP11 in complex with rocuronium

Summary for 9G6Q

• Entry DOI: 10.2210/pdb9g6q/pdb
• Descriptor: scFv-IP11, rocuronium, ... (4 entities in total)
• Functional Keywords: immunotherapy, anaphylaxis, immune system
• Biological source: Mus musculus; More
• Total number of polymer chains: 2
• Total formula weight: 27615.65

Authors

Haouz, A.,Saul, F.A.,Bruhns, P. (deposition date: 2024-07-19, release date: 2025-02-12, Last modification date: 2025-05-21)

Primary citation

Dejoux, A.,Zhu, Q.,Woolfe, A.,Godon, O.,Ellouze, S.,Mottet, G.,Castrillon, C.,Gillis, C.,Pecalvel, C.,Ganneau, C.,Iannascoli, B.,Lemoine, F.,Saul, F.,England, P.,Reber, L.L.,Gouel-Cheron, A.,de Chaisemartin, L.,Haouz, A.,Millot, G.A.,Bay, S.,Gerard, A.,Jonsson, F.,Chollet-Martin, S.,Bruhns, P.
Antibody-secreting cell repertoires hold high-affinity anti-rocuronium specificities that can induce anaphylaxis in vivo.
J.Allergy Clin.Immunol., 155:1557-1574, 2025

PubMed Abstract: Neuromuscular blocking agents (NMBAs) are muscle relaxants used to assist mechanical ventilation but lead in 1 per 10,000 anesthesia cases to severe acute hypersensitivity reactions-that is, anaphylaxis. Incidences vary between types of NMBAs. Rocuronium, a widely used nondepolarizing aminosteroid NMBA, induces among the highest anaphylaxis rates. Rocuronium-induced anaphylaxis is proposed to rely on preexisting rocuronium-binding antibodies, but no such antibodies have ever been identified.

PubMed: 39892658
DOI: 10.1016/j.jaci.2025.01.025

Experimental method

X-RAY DIFFRACTION (1.2 Å)